PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Biogen Idec, Bristol-Myers Squibb, Pfizer, MedImmune and Roche intended to enhance the understanding of and identify more effective methods of predicting, preventing and treating PML.
2013 Request for Grant Proposals Now Available
The PML Consortium has announced its next call for proposals. Topics of interest include PML pathogenesis (JCV virology and host resistance mechanisms), PML risk factors, PML diagnosis, discovery of novel drug targets as a treatment for PML, and management of PML, such as treatment for IRIS.